Real-world cost evaluation of conbercept vs. ranibizumab for retinal and choroidal vascular diseases from 2021 to 2024: evidence from societal and medical insurance perspectives. [PDF]
Liu Y +12 more
europepmc +1 more source
Faricimab for choroidal neovascular membrane secondary to choroidal osteoma: A case report. [PDF]
Al Adel F +3 more
europepmc +1 more source
Efficacy and Safety of Ranibizumab Combined with Dexamethasone Intravitreal Implant Sequential Therapy for Macular Edema Secondary to Non-Ischemic Retinal Vein Occlusion. [PDF]
Gao L, Cai X, Dang Y.
europepmc +1 more source
Evolution of Anti-Vascular Endothelial Growth Factor Clinical Trial Design for Treating Neovascular Age-Related Macular Degeneration. [PDF]
Klufas MA +3 more
europepmc +1 more source
Retinal vein occlusion-related macular edema: An updated review of current evidence and future directions. [PDF]
Temkar S +5 more
europepmc +1 more source
Association of vitreous CREG1 with diabetic macular edema response and edema resolution following ranibizumab therapy. [PDF]
Zhu L +5 more
europepmc +1 more source
Efficacy and safety of ranibizumab, aflibercept, and conbercept in the treatment of diabetic macular edema: a retrospective comparative study. [PDF]
Liu B, Qiao Q, Dang Y.
europepmc +1 more source
Long-Term Management of Polypoidal Choroidal Vasculopathy: A Narrative Review. [PDF]
Koh A +6 more
europepmc +1 more source
Efficacy of brolucizumab and ranibizumab in diabetic macular edema and neovascular age-related macular degeneration: insights from a case series. [PDF]
Hossain B, Rahmatullah S, Ahmed T.
europepmc +1 more source
Systemic and ocular complications related to intravitreal administration of anti-VEGF agents. [PDF]
Koksaldi S +3 more
europepmc +1 more source

